Transglutaminase 2 expression is enhanced synergistically by interferon-γ and tumour necrosis factor-α in human small intestine

Clinical and Experimental Immunology

Volumn 168, Issue 1, 2012, Pages 95-104

  Bayardo, M ^a   Punzi, F ^a   Bondar, C ^a   Chopita, N ^b   Chirdo, F ^a  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

^b Hospital Interzonal General de Agudos de La Plata   (Argentina)

Author keywords

Coeliac disease; IFN ; Inflammation; Transglutaminase 2

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 15; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; SALAZOSULFAPYRIDINE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE MONOCYTIC LEUKEMIA; ARTICLE; CANCER CELL; CELIAC DISEASE; CELL STIMULATION; CELL STRAIN CACO 2; CELL STRAIN HT29; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DUODENUM; DUODENUM MUCOSA; ENZYME INDUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INCUBATION TIME; INTESTINE EPITHELIUM CELL; MONOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

CELIAC DISEASE; CELL LINE; EPITHELIAL CELLS; GTP-BINDING PROTEINS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-1; INTERLEUKIN-15; INTERLEUKIN-6; INTESTINAL MUCOSA; INTESTINE, SMALL; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKOCYTES, MONONUCLEAR; NF-KAPPA B; NITRILES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; SULFASALAZINE; SULFONES; TRANSGLUTAMINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857716111     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04545.x     Document Type: Article

References (30)

1. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003; 4:140-56.
2. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 2002; 27:534-9.
3. Park D, Choi SS, Ha K-S. Transglutaminase 2: a multi-functional protein in multiple subcellular compartments. Amino Acids 2010; 39:619-31.
4. Bayardo MP, De Urraza P, Chirdo FG. Homo sapiens transglutaminase 2 mRNA, complete cds. GenBank Accession number: AY675221.1. 2004 Ago. Available at: (accessed 4 August 2004).
5. Fésüs L, Szondy Z. Transglutaminase 2 in the balance of cell death and survival. FEBS Lett 2005; 579:3297-302.
6. Kim S-Y. Transglutaminase 2 in inflammation. Front Biosci 2006; 11:3026-35.
7. Mehta K, Kumar A, Kim HI. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol 2010; 80:1921-9.
8. Dørum S, Arntzen MØ, Qiao S-W etal. The preferred substrates for transglutaminase 2 in a complex wheat gluten digest are peptide fragments harboring celiac disease T-cell epitopes. PLoS ONE 2010; 5:e14056.
9. Molberg O, Mcadam SN, Körner R etal. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998; 4:713-7.
10. Abadie V, Sollid LM, Barreiro LB, Jabri B. Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Annu Rev Immunol 2011; 29:493-525.
11. Lee J, Kim YS, Choi DH etal. Transglutaminase 2 induces NFκB activation via a novel pathway in BV-2 microglia. J Biol Chem 2004; 279:53725-35.
12. Kuncio GS, Tsyganskaya M, Zhu J etal. TNFα modulates expression of the tissue transglutaminase gene in liver cells. Am J Physiol 1998; 274(Pt 1):G240-245.
13. Boivin MA, Roy PK, Bradley A, Kennedy JC, Rihani T, Ma TY. Mechanism of γIFN-induced increase in T84 intestinal epithelial tight junction. J Interferon Cytokine Res 2009; 29:45-54.
14. Kim S-Y, Jeong E-J, Steinert PM. γIFN induces transglutaminase 2 expression in rat small intestinal cells. J Interferon Cytokine Res 2002; 22:677-82.
15. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 2007; 115:232-45.
16. Di Niro R, Ferrara F, Not T etal. Characterizing monoclonal antibody epitopes by filtered gene fragment phage display. Biochem J 2005; 388(Pt 3):889-94.
17. Kaur S, Uddin S, Platanias LC. The PI3' kinase pathway in interferon signaling. J Interferon Cytokine Res 2005; 25:780-7.
18. Luciani A, Villella VR, Vasaturo A etal. Lysosomal accumulation of gliadin p31-43 peptide induces oxidative stress and tissue transglutaminase-mediated PPARgamma downregulation in intestinal epithelial cells and coeliac mucosa. Gut 2010; 59:311-9.
19. Oh K, Park H-B, Byoun O-J etal. Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice. J Exp Med 2011; 208:1707-19.
20. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351(Pt 1):95-105.
21. Bain J, Plater L, Elliott M etal. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408(Pt 3):297-315.
22. Krishnamurty R, Maly DJ. Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors. ACS Chem Biol 2010; 5:121-38.
23. Clarke CJ, Guthrie JM, Hannun YA. Regulation of neutral sphingomyelinase-2 (nSMase2) by TNFα involves protein kinase C-δ in lung epithelial cells. Mol Pharmacol 2008; 74:1022-32.
24. Haller D, Russo MP, Sartor RB, Jobin C. IKK beta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NFκB activation in both primary and intestinal epithelial cell lines. J Biol Chem 2002; 277:38168-78.
25. Wu T, Mohan C. The AKT axis as a therapeutic target in autoimmune diseases. Endocr Metab Immune Disord Drug Targets 2009; 9:145-50.
26. Dzhambazov B, Lindh I, Engström A, Holmdahl R. Tissue transglutaminase enhances collagen type II-induced arthritis and modifies the immunodominant T-cell epitope CII260-270. Eur J Immunol 2009; 39:2412-23.
27. Villanacci V, Not T, Sblattero D etal. Mucosal tissue transglutaminase expression in celiac disease. J Cell Mol Med 2009; 13:334-40.
28. Elli L, Bergamini CM, Bardella MT, Schuppan D. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig Liver Dis 2009; 41:541-50.
29. Maiuri L, Luciani A, Giardino I etal. Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. J Immunol 2008; 180:7697-705.
30. Caccamo D, Currò M, Ientile R. Potential of transglutaminase 2 as a therapeutic target. Expert Opin Ther Targets 2010; 14:989-1003.